Logo Logo
Switch Language to German
Heinemann, V.; Ebert, M. P.; Laubender, Rüdiger P.; Bevan, P.; Mala, C.; Boeck, S. (2013): Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. In: British Journal of Cancer BJC, Vol. 108, No. 4: pp. 766-770
Full text not available from 'Open Access LMU'.